Eric Siemers, M.D., Named Distinguished Medical Adviser at Cogstate
February 27 2018 - 9:20AM
Business Wire
Siemers will provide expert advice for Cogstate in
neurodegeneration research
The cognitive science company, Cogstate Ltd (ASX.CGS) today
announced the appointment of Eric Siemers, M.D., as Distinguished
Medical Adviser. Dr. Siemers will provide expert advice for
Cogstate’s pharmaceutical customers with regard to the design of
clinical trials of neurodegenerative diseases. He will support
Cogstate’s ongoing participation in industry associations and
public-private partnerships including the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) and the Anti-Amyloid Treatment in
Asymptomatic Alzheimer's Disease study (A4), and he will work to
expand Cogstate’s relationships with academic key opinion leaders.
Dr. Siemers will also support Cogstate’s healthcare solution,
CognigramTM, with research and medical education efforts that
foster the awareness and understanding of the link between regular
cognitive screening and improved health outcomes.
“Dr. Siemers is a leading expert in neurodegenerative disease
and brings a critical external perspective as both a clinician and
researcher,” said Brad O’Connor, Cogstate CEO. “As a science-driven
company we must continue to gain medical and scientific leadership
that deepens our understanding of the current needs of drug
developers, patients and providers, and Eric is the ideal candidate
for advancing that goal.”
About Eric Siemers
Dr. Siemers’ experience in clinical trials of neurodegenerative
disease spans over 25 years, with a research focus on the use of
biomarkers in investigational drug research, the development of
trial designs that fully characterize the effects of
investigational drugs on chronic diseases, and more specifically,
the development of strategies for treating individuals before the
onset of symptoms of neurodegenerative diseases.
Dr. Siemers most recently served as Distinguished Medical Fellow
for Eli Lilly and Company’s Alzheimer’s Disease Global Development
Team, where he was responsible for the design and implementation of
5 large phase III clinical studies of AD sponsored by Lilly, in
addition to playing a major collaborative role in 2 public-private
partnership studies.
Prior to his appointments at Lilly, Dr. Siemers founded and
headed the Indiana University Movement Disorder Clinic; his
research there included investigations of Parkinson’s disease and
Huntington’s disease, and he established one of the first centers
for surgical PD treatments in the US.
Dr. Siemers is a member of the NIA/Alzheimer’s Association
working group that will evaluate biomarkers and clinical symptoms
in the nomenclature used for research of the entire Alzheimer’s
disease continuum, and was previously a member of the working group
that proposed criteria for preclinical Alzheimer’s disease in 2011.
He also served on the Board of Directors of the American Society of
Experimental Neurotherapeutics, as founding member and Chair of the
Alzheimer’s Association Research Roundtable, and Steering Committee
member for the Alzheimer’s Disease Neuroimaging Initiative
(ADNI).
Dr. Siemers earned his MD with highest distinction from the
Indiana University School of Medicine, where he completed an
internship in the Department of Internal Medicine and residency in
the Department of Neurology.
About Cogstate
Cogstate Ltd (ASX:CGS) is a leading science and technology
solutions provider dedicated to optimizing the measurement of
cognition in clinical trials, academic research and healthcare.
Cogstate provides enabling technologies and professional services
for higher quality neuropsychological assessments and is a pioneer
in commercializing rapid, reliable and highly sensitive
computerized cognitive tests. Cogstate customers include the
world’s leading biopharmaceutical companies; elite sporting
organizations and military; physicians and patients; renowned
academic institutions and public-private partnerships. For more
information, please visit www.cogstate.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180227005954/en/
CogstateRachel Colite, 203-773-5010rcolite@cogstate.com
Cogstate (ASX:CGS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Cogstate (ASX:CGS)
Historical Stock Chart
From Nov 2023 to Nov 2024
